Mark S. Kramer

Distinct Mechanism for Antidepressant Activity by Blockade of Central Substance P Receptors

Mark S. Kramer, Neal R. Cutler, John P. Feighner et al. · Science · 1998 · 1.1K citations

Medicine, Pharmacology, Psychiatry +17

Demonstration of the Efficacy and Safety of a Novel Substance P (NK1) Receptor Antagonist in Major Depression

Mark S. Kramer, Andrew Winokur, Jeffrey E. Kelsey et al. · Neuropsychopharmacology · 2003 · 259 citations

Medicine, Pharmacology, Pharmacotherapy +15

The Effects of a Selective D4 Dopamine Receptor Antagonist (L-745,870) in Acutely Psychotic Inpatients With Schizophrenia

Mark S. Kramer · Archives of General Psychiatry · 1997 · 199 citations

Medicine, Pharmacology, Psychiatry +17

A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks

Mark S. Kramer, Deborah Matzura‐Wolfe, A. Polis et al. · Neurology · 1998 · 147 citations

Medicine, Pharmacology, Pharmacotherapy +10

Antidepressants in 'depressed' schizophrenic inpatients. A controlled trial.

Mark S. Kramer, Wolfgang Vogel, Celeste DiJohnson et al. · PubMed · 1989 · 142 citations

Pharmacy, Pharmacotherapy, Psychiatry +12